Amphastar Pharmaceuticals (AMPH) Other Non-Current Assets (2013 - 2026)
Amphastar Pharmaceuticals (AMPH) posted quarterly Other Non-Current Assets of $33.5 million for Q1 2026, up 45.62% year-over-year from $23.0 million in Q1 2025, and up 7.53% quarter-over-quarter from $31.1 million in Q4 2025.
Amphastar Pharmaceuticals (AMPH) Other Non-Current Assets (2013 - 2026) Analysis & Trends
Amphastar Pharmaceuticals' Other Non-Current Assets history runs 14 years deep, the most recent figure standing at $33.5 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 45.62% year-over-year to $33.5 million; the TTM figure through Mar 2026 stood at $33.5 million (up 45.62% YoY), while the FY2025 annual figure was $31.1 million, up 19.79% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $33.5 million, up from $31.1 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $33.5 million in Q1 2026, with the low at $16.3 million in Q1 2022.
- The 5-year median for Other Non-Current Assets is $23.7 million (2024), against an average of $24.1 million.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets surged 126.03% in 2022, then slipped 6.47% in 2024.
- Amphastar Pharmaceuticals' Other Non-Current Assets stood at $20.9 million in 2022, then advanced by 24.23% to $25.9 million in 2023, then rose by 0.32% to $26.0 million in 2024, then rose by 19.79% to $31.1 million in 2025, then grew by 7.53% to $33.5 million in 2026.
- Business Quant data shows AMPH's Other Non-Current Assets at $33.5 million in Q1 2026, $31.1 million in Q4 2025, and $29.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 13.00 Mn |
| 10 | Amphastar Pharmaceuticals | 943.15 Mn | 653.02 Mn | 93.47 Mn | 33.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.39 Mn |
| Mar 31, 2026 | 33.48 Mn |
| Dec 31, 2025 | 31.14 Mn |
| Sep 30, 2025 | 29.87 Mn |
| Jun 30, 2025 | 28.10 Mn |
| Mar 31, 2025 | 22.99 Mn |
| Dec 31, 2024 | 25.99 Mn |
| Sep 30, 2024 | 23.66 Mn |
| Jun 30, 2024 | 24.26 Mn |
| Mar 31, 2024 | 23.37 Mn |
| Dec 31, 2023 | 25.91 Mn |
| Sep 30, 2023 | 25.30 Mn |
| Jun 30, 2023 | 20.27 Mn |
| Mar 31, 2023 | 18.54 Mn |
| Dec 31, 2022 | 20.86 Mn |
| Sep 30, 2022 | 20.55 Mn |
| Jun 30, 2022 | 18.68 Mn |
| Mar 31, 2022 | 16.30 Mn |
| Dec 31, 2021 | 16.67 Mn |
| Sep 30, 2021 | 11.61 Mn |